Journal Home
Search for

Volume 37, Issue 4, Pages 355-358 (November 2009)


View previous. 4 of 51 View next.

Contraindications to Phenytoin in Emergency Department Patients with Seizures

Robert Murphy, BS, Jill Daugherty, MPH, Debra Houry, MD, MPHCorresponding Author Information

Received 20 February 2007; received in revised form 8 June 2007; accepted 9 August 2007. published online 07 March 2008.

Abstract 

The objective of this study was to determine what contraindications to phenytoin exist in Emergency Department (ED) patients with a medical history of seizures. We conducted a retrospective chart review using ED medical records from 2005 at two network health care EDs. We identified potential patients through ICD-9 (International Classification of Diseases, Ninth Revision) codes, selected only adult patients with a prior documented history of seizures, and reviewed these charts. From 201 charts reviewed, the three most common antiepileptic drugs taken by patients were: phenytoin (38%), levetiracetam (17%), and valproic acid (15%). For absolute contraindications to phenytoin, 4.5% of seizure patients had a known hypersensitivity to phenytoin and 1.5% were pregnant; however, no pregnant patients were taking phenytoin and only 1 person with hypersensitivity to phenytoin was taking phenytoin. For relative contraindications, 6% of seizure patients had liver disease, 8% had kidney disease, 9% had alcohol use/dependence, and 16% had diabetes. However, 55% of those with liver disease, 44% with kidney disease, 77% with alcohol use/dependence, and 53% with diabetes were currently taking phenytoin. Very few seizure patients in the ED have absolute contraindications to the use of phenytoin, and most with absolute contraindications are taking other antiepileptic drugs. Conversely, a greater proportion of seizure patients have relative contraindications and many are continuing to use phenytoin.

 Emory University School of Medicine, Emory University, Atlanta, Georgia

 Department of Emergency Medicine, Emory University, Atlanta, Georgia

Corresponding Author InformationReprint Address: Debra Houry, md, mph, Emory University, 49 Jesse Hill Jr. Dr. SE #114, Atlanta, GA 30303

 This work was funded by UCB Pharma, Smyrna, GA.

PII: S0736-4679(07)00832-3

doi:10.1016/j.jemermed.2007.08.067


View previous. 4 of 51 View next.